Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;33(2):131-138.
doi: 10.1097/ACO.0000000000000813.

Antifungal use in the surgical ICU patient

Pedro Póvoa  1   2   3 , Luís Coelho  1   2 , David Nora  1   2 , Ignacio Martin-Loeches  4   5   6
Affiliations
Review

Antifungal use in the surgical ICU patient

Pedro Póvoa et al. Curr Opin Anaesthesiol. 2020 Apr.

Abstract

Purpose of review: The successful treatment of surgical fungal infections depends of a timely and adequate source control alongside with the use of prompt systemic antifungals. The main challenge of antifungal use in critically ill surgical patients is to find a balance between rational versus indiscriminate use in order to accomplish an antifungal stewardship program.

Recent findings: Surgical fungal infections represent an important burden in the daily clinical activity in many ICUs. The efficacy of the available antifungal drugs has not been adequately assessed in randomized controlled trials with surgical fungal infections in ICU patients. Most clinical experience is limited to case reports or uncontrolled case series. Due to the lack of adequate scientific evidence to assess the role of the different antifungals in surgical ICU patients, it is usually suggested to follow the recommendations for invasive candidiasis and candidemia.

Summary: Antifungal use in the surgical patients admitted to an ICU is a complex matter and there are several elements to consider like the presence of septic shock and multiorgan failure, local epidemiology and antifungal resistance, among others. The proper use of antifungals alongside early recognition and prompt source control, are critical factors for improved outcomes.

PubMed Disclaimer

References

    1. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1–50.
    1. Vincent JL, Rello J, Marshall J, et al. EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323–2329.
    1. Baldesi O, Bailly S, Ruckly S, et al. ICU-acquired candidaemia in France: epidemiology and temporal trends, 2004-2013 - a study from the REA-RAISIN network. J Infect 2017; 75:59–67.
    1. Oh YW, Effmann EL, Godwin JD. Pulmonary infections in immunocompromised hosts: the importance of correlating the conventional radiologic appearance with the clinical setting. Radiology 2000; 217:647–656.
    1. Buckley RH. Immunodeficiency diseases. JAMA 1987; 258:2841–2850.

MeSH terms

Substances